FAM156A Antibody

What are the validated applications for FAM156A antibody?

FAM156A antibody has been validated for multiple laboratory applications including Western Blot (WB), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunofluorescence (IF). When selecting a FAM156A antibody for your research, it is important to verify that it has been validated for your specific application of interest. The validation data shows particularly strong performance in IHC applications, where it has been successfully used to detect FAM156A in human lung cancer tissue, human heart tissue, human liver tissue, and mouse heart tissue . For Western blotting applications, the antibody has been validated in PC-13 cells . Researchers should optimize the antibody concentration for each specific application and sample type.

What is the recommended dilution range for different applications?

The optimal dilution varies depending on the specific application:

It is highly recommended that researchers perform a titration experiment in each testing system to determine the optimal antibody concentration for their specific experimental conditions . The optimal dilution may vary based on the detection method, sample type, and target abundance in your specific experimental system.

What are the optimal antigen retrieval conditions for FAM156A immunohistochemistry?

For optimal antigen retrieval in IHC applications, the recommended protocol is to use TE buffer at pH 9.0. If this does not yield satisfactory results, an alternative approach is to use citrate buffer at pH 6.0 . The choice between these two methods may depend on your specific tissue type, fixation method, and processing procedures. Researchers should compare both methods to determine which provides the best signal-to-noise ratio for their specific tissue samples. It is advisable to include positive control tissues (such as human lung cancer tissue, human heart tissue, or mouse heart tissue) to validate the effectiveness of the antigen retrieval method.

How should FAM156A antibody be stored for maximum stability?

FAM156A antibody should be stored at -20°C where it remains stable for up to one year after shipment . The antibody is typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For smaller aliquots (20μl), the formulation may contain 0.1% BSA. Importantly, aliquoting is generally unnecessary for -20°C storage, which simplifies laboratory handling procedures. Avoid repeated freeze-thaw cycles as this can lead to protein denaturation and loss of antibody activity. Always centrifuge the antibody vial briefly before opening to ensure the solution is at the bottom of the vial.

How can I validate the specificity of my FAM156A antibody results?

To validate the specificity of FAM156A antibody results, multiple approaches should be employed:

• Use positive control samples where FAM156A expression is well-documented, such as PC-13 cells for Western blotting or human lung cancer tissue for IHC .

• Implement a blocking peptide competition assay using the FAM156A immunogen to demonstrate signal specificity.

• Compare results across multiple detection methods (e.g., WB, IHC, IF) to confirm consistent expression patterns.

• Consider using RNA interference (siRNA or shRNA) to knockdown FAM156A expression and demonstrate corresponding reduction in antibody signal.

• For advanced validation, CRISPR/Cas9-mediated knockout can be employed to generate negative control samples.

This multi-faceted approach ensures that the observed signals are specifically attributed to FAM156A rather than non-specific binding or cross-reactivity.

What is the relationship between FAM156A and FAM156B, and how might this affect antibody specificity?

FAM156A and FAM156B are closely related proteins, both also known as transmembrane proteins 29 and 29B respectively . The immunogen used for the antibody production is described as "Recombinant Human Protein FAM156A/FAM156B protein (1-153AA)" , suggesting potential cross-reactivity between these two proteins. This relationship is important to consider when interpreting experimental results.

Researchers investigating specific roles of either FAM156A or FAM156B should implement additional controls to distinguish between these proteins. Western blot analysis can help differentiate the proteins based on their molecular weights, though the calculated molecular weight of FAM156A is reported as 24 kDa . For definitive differentiation, researchers may need to employ isoform-specific primers in complementary RT-PCR experiments or use mass spectrometry-based protein identification approaches to confirm which specific variant is being detected in their experimental system.

What is known about the cellular localization and function of FAM156A?

FAM156A (also known as TMEM29) is a transmembrane protein , which suggests localization to membrane structures within the cell. While the specific cellular functions of FAM156A are not extensively documented in the provided search results, its classification as a transmembrane protein implies potential roles in:

• Signal transduction across cellular membranes

• Transport of molecules across membranes

• Cell-cell communication or adhesion

• Maintenance of cellular or organelle membrane structure

Researchers investigating FAM156A function should consider its transmembrane nature when designing experimental approaches. Immunofluorescence co-localization studies with established markers for various cellular membranes (plasma membrane, ER, Golgi, nuclear envelope, etc.) would be valuable to determine the precise subcellular localization of this protein. This information would provide insights into potential functional roles within specific cellular compartments.

How can I optimize protein extraction for FAM156A detection in Western blotting?

For effective detection of transmembrane proteins like FAM156A in Western blotting applications, consider the following optimization strategies:

• Use extraction buffers containing strong detergents suitable for membrane proteins, such as RIPA buffer supplemented with 0.5-1% SDS or NP-40.

• Include protease inhibitor cocktails to prevent degradation during the extraction process.

• For tough-to-extract membrane proteins, consider using specialized membrane protein extraction kits that employ stronger solubilization methods.

• Optimize sonication or homogenization parameters to ensure efficient cellular disruption without protein degradation.

• Avoid excessive heat during sample preparation, as transmembrane proteins can aggregate when heated for extended periods.

• For Western blot transfer, consider using optimized protocols for hydrophobic proteins, such as adding 0.05-0.1% SDS to the transfer buffer or increasing the transfer time.

For FAM156A specifically, the recommended dilution range for Western blotting is 1:200-1:1000 , but this should be optimized based on your specific sample type and protein abundance.

What controls should be included in FAM156A immunohistochemistry experiments?

A robust experimental design for FAM156A IHC studies should include the following controls:

• Positive tissue controls: Include human lung cancer tissue, human heart tissue, human liver tissue, or mouse heart tissue, which have been validated as positive for FAM156A expression .

• Negative controls: Include tissues known not to express FAM156A or use isotype control antibodies at the same concentration as the FAM156A antibody.

• Technical negative controls: Perform the IHC protocol with omission of the primary antibody to assess potential background from the secondary detection system.

• Antigen competition controls: Pre-incubate the FAM156A antibody with excess immunizing peptide to demonstrate specificity of the staining pattern.

• Comparative staining: If available, use alternative FAM156A antibodies raised against different epitopes to confirm staining patterns.

These controls collectively help validate the specificity and reliability of the observed staining patterns, particularly important when examining FAM156A expression in previously uncharacterized tissues or disease states.

How should I approach FAM156A expression analysis in cancer research studies?

When investigating FAM156A expression in cancer research, consider these methodological approaches:

• Perform comparative IHC analysis between tumor tissue and matched normal adjacent tissue to evaluate expression differences. FAM156A antibody has been validated for human lung cancer tissue , making it a good starting point for cancer studies.

• Use tissue microarrays to efficiently screen FAM156A expression across multiple cancer types and stages.

• Correlate FAM156A expression with clinicopathological parameters and patient outcomes to assess potential prognostic value.

• Complement protein-level studies with mRNA expression analysis using qRT-PCR or RNA-Seq to determine if expression changes occur at the transcriptional or post-transcriptional level.

• Consider developing stable cell lines with FAM156A knockdown or overexpression to investigate functional consequences in cancer-relevant assays (proliferation, migration, invasion, etc.).

For IHC applications in cancer tissues, the recommended antibody dilution range is 1:50-1:500 , but optimization is essential for each specific cancer type and tissue processing method.

What are effective troubleshooting strategies for weak or inconsistent FAM156A antibody signals?

When encountering weak or inconsistent FAM156A antibody signals, implement these troubleshooting strategies:

• For Western blot applications:

  • Increase protein loading amount (up to 50-100 μg of total protein)

  • Reduce antibody dilution (try 1:200 instead of 1:1000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try enhanced detection systems with higher sensitivity

  • Optimize transfer conditions for better protein transfer efficiency

• For IHC applications:

  • Experiment with different antigen retrieval methods (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Increase antibody concentration (try 1:50 dilution)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try amplification systems such as tyramide signal amplification

  • Ensure tissues are properly fixed and processed

• For all applications:

  • Verify sample integrity and preparation techniques

  • Check antibody storage conditions and expiration

  • Include known positive controls in each experiment

  • Consider batch effects if inconsistencies are observed between experiments

Systematic troubleshooting using these approaches should help identify the source of signal issues and lead to more consistent and reliable results in FAM156A detection experiments.